These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37108037)

  • 1. Editorial to the
    Lymperopoulos A
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of sodium-glucose cotransporter 2 inhibitors beyond the cardio-renal-metabolic spectrum: will gliflozins have a different fate than statins?
    Koufakis T; Tsimihodimos V; Metallidis S; Kotsa K; Doumas M
    Expert Opin Pharmacother; 2023; 24(16):1753-1756. PubMed ID: 37594789
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
    Kumar S; Khatik GL; Mittal A
    Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.
    Maccari R; Ottanà R
    J Med Chem; 2022 Aug; 65(16):10848-10881. PubMed ID: 35924548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [From the discovery of phlorizin (a Belgian story) to SGLT2 inhibitors].
    Valdes-Socin H; Scheen AJ; Jouret F; Grosch S; Delanaye P
    Rev Med Liege; 2022 Mar; 77(3):175-180. PubMed ID: 35258866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
    Kyriakos G; Quiles-Sanchez LV; Garmpi A; Farmaki P; Kyre K; Savvanis S; Antoniou VK; Memi E
    Curr Cardiol Rev; 2020; 16(4):258-265. PubMed ID: 31362691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
    Haider K; Pathak A; Rohilla A; Haider MR; Ahmad K; Yar MS
    Eur J Med Chem; 2019 Dec; 184():111773. PubMed ID: 31630053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The growing clinical effect of SGLT2 inhibitors.
    Del Prato S
    Lancet Diabetes Endocrinol; 2023 Apr; 11(4):218-219. PubMed ID: 36878241
    [No Abstract]   [Full Text] [Related]  

  • 11. "The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics".
    Kaur P; Behera BS; Singh S; Munshi A
    Eur J Pharmacol; 2021 Aug; 904():174169. PubMed ID: 33984301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection.
    Aroda VR; Billings LK
    J Am Coll Cardiol; 2023 Aug; 82(6):526-528. PubMed ID: 37532423
    [No Abstract]   [Full Text] [Related]  

  • 14. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors.
    Fender AC; Dobrev D
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Apr; 396(4):589-592. PubMed ID: 36943455
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming.
    Gao YM; Feng ST; Wen Y; Tang TT; Wang B; Liu BC
    EBioMedicine; 2022 Sep; 83():104215. PubMed ID: 35973390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes.
    Packer M
    Diabetes Obes Metab; 2023 May; 25(5):1143-1146. PubMed ID: 36583283
    [No Abstract]   [Full Text] [Related]  

  • 18. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
    Pandey J; Tamrakar AK
    Expert Opin Ther Pat; 2019 May; 29(5):369-384. PubMed ID: 31026402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors.
    Gunasekaran D; Shirali AC
    Kidney360; 2023 Sep; 4(9):e1322-e1324. PubMed ID: 37487034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.